Healthcare

Popular Topics in Healthcare

Explore all subjects

The Expertise Imperative and Compliance Technology: Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework

This page may include content provided by Council Members, your access to which is subject to the Terms of Use.

Find Out More

Become a GLG Client

All GLG News Analyses Filed Under: Endocrinology

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

November 13, 2006
Could be the drug of the decade - but depression worrying side effect

By a GLG Expert Contributor

Analysis of: Acomplia (Rimonabant) - Investigational Agent for the Management of Obesity | www.drugdevelopment-technology.com

- With the explosion of obesity and obesity related illness in the western world a safe, effective, long term weight loss drug is one of the holy grails of the pharmaceutical industry- Rimonabant has been proven effective in long-term use, but there are unresolved questions about depression as a side...

Forrest Rubenstein, MD, Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic Surgery

November 13, 2006
Advanced treatment for hypercholesterolemia - Torcetrapib raises HDL

Analysis of: Pfizer Updates Preliminary Results Of Torcetrapib/Atorvastatin Clinical Trials As Abstract For Phase 3 Study Is Released | www.medicalnewstoday.com

The mainstay of treatment for hypercholesterolemia now is a statin drug (HMG CoA reductase inhibitor) to reduce LDL levels.These statin drugs have been proven to reduce LDL cholesterol and to reduce cardiac events.Another major independent cardiovascular risk factor is low levels of HDL cholesterol...

November 13, 2006
A long way to go...

By a GLG Expert Contributor

Analysis of: Emisphere Technologies Demonstrates Safety and Efficacy of Oral Insulin in Phase 2 Trial in Type 2 Diabetics | www.emisphere.com

Good proof of conceptNeeds lots more dataCost of final product will be key

November 10, 2006
Continued good news for Torcetrapib

By a GLG Expert Contributor

Analysis of: Pfizer Updates Preliminary Results Of Torcetrapib/Atorvastatin Clinical Trials As Abstract For Phase 3 Study Is Released | www.medicalnewstoday.com

- Effective lipid modification (HDL raising and LDL lowering) shown.- Outcomes data (mortality) still needed- Lower side effects make torcetrapib attractive

November 10, 2006
What will the FDA require to approve torcetrapib?

By a GLG Expert Contributor

Analysis of: Pfizer Updates Preliminary Results Of Torcetrapib/Atorvastatin Clinical Trials As Abstract For Phase 3 Study Is Released | www.medicalnewstoday.com

It has become increasingly clear that the FDA requires "clinically relevant" endpoints for approval of cardiovascular drugs and devices.

November 6, 2006
The sky's the limit for the prevalence of obesity with improved treatments of Type 2 Diabetes

By a GLG Expert Contributor

Analysis of: Emisphere Technologies Demonstrates Safety and Efficacy of Oral Insulin in Phase 2 Trial in Type 2 Diabetics | www.emisphere.com

One of the major deterrents for patients that has made them amenable to lifestyle interventions for Type 2 diabetes is the fear of needing regular injections of insulin.

November 3, 2006
Useless Oral Insulin

By a GLG Expert Contributor

Analysis of: Emisphere Technologies Demonstrates Safety and Efficacy of Oral Insulin in Phase 2 Trial in Type 2 Diabetics | www.emisphere.com

Emisphere showed that at high doses their product can have a slight impact on blood sugar; however, it has not been able to demonstrate an accurate dose response curve.

October 30, 2006
Oral Insulin

By a GLG Expert Contributor

Analysis of: Emisphere Technologies Demonstrates Safety and Efficacy of Oral Insulin in Phase 2 Trial in Type 2 Diabetics | www.emisphere.com

A dose (10mg QID) showed statistical response vs placebo, though other doses (10 mg BID and 5 mg QID) did not.

October 27, 2006
Rosiglitazone decreases development of diabetes by greater than 50%

By a GLG Expert Contributor

Analysis of: DREAM: Rosiglitazone Effective in Preventing Diabetes | www.medscape.com

Rosiglitazone reduced the development of diabetes in patients with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) in the DREAM study. 5269 patients over age 30 with IFG or IGT but without pre-existing cardiovascular disease were randomized to 8 mg rosiglitazone daily...

Glen McDaniel, MS, MBA, President and Chief Executive Officer
GM Global

October 27, 2006
Junevia promises hope for better diabetic control

Analysis of: FDA Approves New Treatment for Diabetes First in a New Class of Diabetes Drugs | www.fda.gov

Junevia offers real hope in the treatment of diabetes for several reasons:- the method of action is different from current meds- the side effects are minimal compared to medications of similar efficacy- it offers a choice of meds since it can be used in combination- it should be...

Previous Page : 27 28 29 30 31 32 33 34 35 36 37 38 Next361 to 370 of 375

Subscribe to Updates

By RSS